A therapeutic approach to hyperglycaemia in the setting of acute myocardial infarction: Spotlight on glucagon-like peptide 1

Therapeutic Advances in Cardiovascular Disease

Volumn 6, Issue 5, 2012, Pages 213-219

  Egom, Emmanuel Eroume A ^a  

^a UNIVERSITY OF HULL   (United Kingdom)

Author keywords

acute myocardial infarction (AMI); glucagon like peptide 1 (GLP 1)

Indexed keywords

CATECHOLAMINE; EXENDIN 4; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 [7-36] AMIDE; GLUCOSE; HYDROCORTISONE; INTERLEUKIN 1; INTERLEUKIN 6; LIRAGLUTIDE; SITAGLIPTIN; SPHINGOSINE 1 PHOSPHATE; TUMOR NECROSIS FACTOR;

ACUTE HEART INFARCTION; ACUTE KIDNEY FAILURE; ACUTE PANCREATITIS; BODY WEIGHT; GASTROINTESTINAL DISEASE; GLUCOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLYCOGENOLYSIS; HEART PROTECTION; HUMAN; HYPERGLYCEMIA; HYPOTHALAMUS HYPOPHYSIS SYSTEM; IMMUNE RESPONSE; INSULIN RESISTANCE; KIDNEY FAILURE; LIPOLYSIS; MEDICAL LITERATURE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; SIDE EFFECT; TREATMENT OUTCOME;

ANIMALS; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE; HUMANS; HYPERGLYCEMIA; INSULIN RESISTANCE; LYSOPHOSPHOLIPIDS; MYOCARDIAL INFARCTION; SPHINGOSINE;

EID: 84867286155     PISSN: 17539447     EISSN: 17539455     Source Type: Journal    
DOI: 10.1177/1753944712457598     Document Type: Article

References (50)

1. Amori R. Lau J. Pittas A.G. (2007) Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 298: 194–206.
2. Ban K. Noyan-Ashraf M. Hoefer J. Bolz S. Drucker D. Husain M. (2008) Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 117: 2340–2350.
3. Bao W. Aravindhan K. Alsaid H. Chendrimada T. Szapacs M. Citerone D. et al. (2011) Albiglutide, a long lasting glucagon-like peptide-1 analog, protects the rat heart against ischemia / reperfusion injury: evidence for improving cardiac metabolic efficiency. PloS ONE 6: e23570.
4. Barth E. Albuszies G. Baumgart K. Matejovic M. Wachter U. Vogt J. et al. (2007) Glucose metabolism and catecholamines. Crit Care Med 35(9 Suppl.): S508–S518.
5. Bartnik M. Ryden L. Ferrari R. Malmberg K. Pyorala K. Simoons M. et al. (2004) The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on Diabetes and the Heart. Eur Heart J 25: 1880–1890.
6. Bose A. Mocanu M. Carr R. Brand C. Yellon D. (2005 a) Glucagon-like peptide 1 can directly protect the heart against ischemia / reperfusion injury. Diabetes 54: 146–151.
7. Bose A. Mocanu M. Carr R. Yellon D. (2005 b) Glucagon like peptide-1 is protective against myocardial ischemia / reperfusion injury when given either as a preconditioning mimetic or at reperfusion in an isolated rat heart model. Cardiovasc Drugs Ther 19: 9–11.
8. Budde K. Schutz M. Glander P. Peters H. Waiser J. Liefeldt L. et al. (2006) FTY 720 (fingolimod) in renal transplantation. Clin Transplant 20(Suppl. 17): 17–24.
9. Buse J. Henry R. Han J. Kim D. Fineman M. Baron A. (2004) Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 27: 2628–2635.
10. Buteau J. Roduit R. Susini S. Prentki M. (1999) Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)-cells. Diabetologia 42: 856–864.
11. Chrousos G. (1995) The hypothalamic–pituitary–adrenal axis and immune-mediated inflammation. N Engl J Med 332: 1351–1362.
12. de Fronzo R. Ratner R. Han J. Kim D. Fineman M. Baron A. (2005) Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 28: 1092–1100.
13. del Aguila L. Claffey K. Kirwan J. (1999) TNF-alpha impairs insulin signaling and insulin stimulation of glucose uptake in C2C12 muscle cells. Am J Physiol 276: E849–E855.
14. Dokken B. La Bonte L. Davis-Gorman G. Teachey M. Seaver N. McDonagh P. (2011) Glucagon-like peptide-1 (GLP-1), immediately prior to reperfusion, decreases neutrophil activation and reduces myocardial infarct size in rodents. Horm Metab Res 43: 300–305.
15. Domanski M. Krause-Steinrauf H. Deedwania P. Follmann D. Ghali J. Gilbert E. et al. (2003) The effect of diabetes on outcomes of patients with advanced heart failure in the BEST trial. J Am Coll Cardiol 42: 914–922.
16. Egom E.E. Ke Y. Musa H. Mohamed T. Wang T. Cartwright E. et al. (2010 a) FTY 720 prevents ischemia / reperfusion injury-associated arrhythmias in an ex vivo rat heart model via activation of Pak1/Akt signaling. J Mol Cell Cardiol 48: 406–414.
17. Egom E.E. Ke Y. Solaro R. Lei M. (2010 b) Cardioprotection in ischemia / reperfusion injury: spotlight on sphingosine-1-phosphate and bradykinin signalling. Prog Biophys Mol Biol 103: 142–147.
18. Elashoff M. Matveyenko A. Gier B. Elashoff R. Butler P.C. (2011) Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 141: 150–156.
19. Frangogiannis N. Smith C. Entman M. (2002) The inflammatory response in myocardial infarction. Cardiovasc Res 53: 31–47.
20. Gauna C. van den Berghe G. van der Lely A. (2005) Pituitary function during severe and life-threatening illnesses. Pituitary 8: 213–217.
21. Gearhart M. Parbhoo S. (2006) Hyperglycemia in the critically ill patient. AACN Clin Issues 17: 50–55.
22. Goode K. John J. Rigby A. Kilpatrick E. Atkin S. Bragadeesh T. et al. (2009) Elevated glycated haemoglobin is a strong predictor of mortality in patients with left ventricular systolic dysfunction who are not receiving treatment for diabetes mellitus. Heart 95: 917–923.
23. Hausenloy D. Yellon D. (2004) New directions for protecting the heart against ischaemia-reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway. Cardiovasc Res 61: 448–460.
24. Holst J. (2007) The physiology of glucagon-like peptide 1. Physiol Rev 87: 1409–1439.
25. Holz G. Leech C. Habener J. (1995) Activation of a cAMP-regulated Ca(2+)-signaling pathway in pancreatic beta-cells by the insulinotropic hormone glucagon-like peptide-1. J Biol Chem 270: 17749–17757.
26. Hui H. Nourparvar A. Zhao X. Perfetti R. (2003) Glucagon-like peptide-1 inhibits apoptosis of insulin-secreting cells via a cyclic 5′-adenosine monophosphate-dependent protein kinase A- and a phosphatidylinositol 3-kinase-dependent pathway. Endocrinol 144: 1444–1455.
27. Hunt D. Ivy J. (2002) Epinephrine inhibits insulin-stimulated muscle glucose transport. J Appl Physiol 93: 1638–1643.
28. Inzucchi S. McGuire D. (2008) New drugs for the treatment of diabetes: part II: incretin-based therapy and beyond. Circulation 117: 574–584.
29. Kendall D. Riddle M. Rosenstock J. Zhuang D. Kim D. Fineman M. et al. (2005) Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 28: 1083–1091.
30. Kwon G. Pappan K. Marshall C. Schaffer J. McDaniel M. (2004) cAMP Dose-dependently prevents palmitate-induced apoptosis by both protein kinase A- and cAMP-guanine nucleotide exchange factor-dependent pathways in beta-cells. J Biol Chem 279: 8938–8945.
31. Lakhdar A. Stromberg P. McAlpine S. (1984) Prognostic importance of hyperglycaemia induced by stress after acute myocardial infarction. Br Med J (Clin Res Ed) 288: 288.
32. Laychock S. Tian Y. Sessanna S. (2003) Endothelial differentiation gene receptors in pancreatic islets and INS-1 cells. Diabetes 52: 1986–1993.
33. Leor J. Nesto R. Kloner R. (1993) Acute myocardial infarction and diabetes mellitus. Cardiovasc Res 27: 1913–1915.
34. Lønborg J. Vejlstrup N. Kelbæk H. Bøtker H. Kim W. Mathiasen A. et al. (2011) Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur Heart J 14 September (epub ahead of print). Available at: http://eurheartj.oxfordjournals.org/content/early/2011/09/13/eurheartj.ehr309.abstract (accessed 23 July 2012).
35. Mocanu M. Bell R. Yellon D. (2002) PI 3 kinase and not p42/p44 appears to be implicated in the protection conferred by ischemic preconditioning. J Mol Cell Cardiol 34: 661–668.
36. Nauck M. Holst J. Willms B. Schmiegel W. (1997) Glucagon-like peptide 1 (GLP-1) as a new therapeutic approach for type 2-diabetes. Exp Clin Endocrinol Diabetes 105: 187–195.
37. Nikolaidis L. Elahi D. Shen Y. Shannon R. (2005) Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy. Am J Physiol Heart Circ Physiol 289: H2401–H2408
38. Nikolaidis L. Mankad S. Sokos G. Miske G. Shah A. Elahi D. et al. (2004) Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 109: 962–965.
39. Norhammar A. Tenerz A. Nilsson G. Hamsten A. Efendic S. Ryden L. et al. (2002) Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet 359: 2140–2144.
40. Opie L. (1975) Metabolism of free fatty acids, glucose and catecholamines in acute myocardial infarction. Relation to myocardial ischemia and infarct size. Am J Cardiol 36 (7): 938–953, http://www.ncbi.nlm.nih.gov/pubmed/1106170.
41. Oswald G.A. Corcoran S. Yudkin J.S. (1984) Prevalence and risks of hyperglycaemia and undiagnosed diabetes in patients with acute myocardial infarction. Lancet 1: 1264–1267.
42. Scholte M. Timmers L. Bernink F. Denham R. Beek A. Kamp O. et al. (2011) Effect of additional treatment with Exenatide in patients with an Acute Myocardial Infarction (EXAMI): study protocol for a randomized controlled trial. Trials 12: 240.
43. Scirica B. Bhatt D. Braunwald E. Steg P. Davidson J. Hirshberg B. et al. (2011) The design and rationale of the saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR-TIMI) 53 study. Am Heart J 162: 818–825.
44. Seematter G. Binnert C. Martin J. Tappy L. (2004) Relationship between stress, inflammation and metabolism. Curr Opin Clin Nutr Metab Care 7: 169–173.
45. Tong H. Chen W. Steenbergen C. Murphy E. (2000) Ischemic preconditioning activates phosphatidylinositol-3-kinase upstream of protein kinase C. Circ Res 87: 309–315.
46. US Food and Drug Administration (2012) MedWatch The FDA Safety Information and Adverse Event Reporting Program: Safety Information – Byetta (exenatide) – renal failure. Available at: http://www.fda.gov/safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm188703.htm (accessed 2 December 2009).
47. van den Berghe G. (2000) Novel insights into the neuroendocrinology of critical illness. Eur J Endocrinol 143: 1–13.
48. Wei Y. Mojsov S. (1995) Tissue-specific expression of the human receptor for glucagon-like peptide-I: brain, heart and pancreatic forms have the same deduced amino acid sequences. FEBS Lett 358: 219–224.
49. Xie Y. Wang S. Sha W. Zhou X. Wang W. Han L. et al. (2008) Effects and mechanism of glucagon-like peptide-1 on injury of rats cardiomyocytes induced by hypoxia-reoxygenation. Chin Med J 121: 2134–2138.
50. Zinman B. Hoogwerf B. Duran Garcia S. Milton D. Giaconia J. Kim D. et al. (2007) The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 146: 477–485.